Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines AgencyAndrew S. Levey, Kerry Willis, Hiddo J.L. Heerspink et al.|American Journal of Kidney Diseases|2019Cited by 561
GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled TrialsLesley A. Inker, Tom Greene, Hiddo J.L. Heerspink et al.|Journal of the American Society of Nephrology|2019Cited by 295